Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Anthony Traboulsee et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Brian G. Weinshenker, Benjamin Greenberg et al.|The Lancet Neurology|2020Cited by 495
An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune SystemsPeggy P. Ho, Hideki Garren|The Journal of Immunology|2003Cited by 85
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosisBenjamin Turner, Stephen L. Hauser, Bruce Cree et al.|Journal of Neurology|2019Cited by 84